Skip to main content

Table 1 Characteristics of the study sample

From: Transbronchial lung biopsy for the diagnosis of lymphangioleiomyomatosis: the severity of cystic lung destruction assessed by the modified Goddard scoring system as a predictor for establishing the diagnosis

 Total
(N = 19)
TBLBP value
positive
(N = 15)
negative
(N = 4)
Age41 (29–58)42 (29–58)40 (37–49)0.928
mMRC score
0/1/2
2/12/52/10/30/2/20.219
Smoking history 0.530
 never
 ex-smoker
14
5
10
5
4
0
 
Serum VEGF-D (pg/mL)2324.7
(457.3–5932.1)
3138.8
(516.9–5932.1)
2213.6
(457.3–2324.7)
0.263
Extrapulmonary LAM lesions 11830.603
Pulmonary function tests
 VC (%pred)101.7
(77.3–126.4)
101.7
(77.3–126.4)
96.8
(79.8–105.4)
0.460
 FEV1(%pred)64.8
(37.6–89.0)
62.0
(37.6–89.0)
66.7
(59.3–81.1)
0.539
 FEV1/FVC (%)73.4
(35.4–103.4)
71.1
(35.4–103.4)
81.8
(70.0–90.3)
0.307
 DLco (%pred)36.3
(20.9–65.9)
36.3
(26.6–64.4)
38.5
(20.9–65.9)
0.980
MGS2.72
(0.92–3.61)
2.72
(1.17–3.61)
2.08
(0.92–2.89)
0.017
  1. Values are presented as counts, median values (range)
  2. Each pack-years is 1.4, 3.5, 6, 7 and 34
  3. Extrapulmonary LAM includes lymphangioleiomyoma of the mediastinum, retroperitoneum, and pelvis
  4. Abbreviations: DLco, diffusing capacity of carbon monoxide; FEV1, forced expiratory volume in 1 s; FVC, forced vital capacity; LAM, lymphangioleiomyomatosis; MGS, modified Goddard score; mMRC, modified Medical Research Council; TBLB, transbronchial lung biopsy; VC, vital capacity; VEGF-D, vascular endothelial growth factor-D; %pred, % of the predicted volume